BrainStorm Live Episode 14: Impact of Amprion’s Early Detection Technology
Amprion’s CEO Dr. Russ Lebovitz talks about the company’s breakthrough Prion Early Detection Testing℠ for Alzheimer’s and Parkinson’s using blood samples. This application is an extension of Amprion’s current Prion Detection Testing using spinal fluids (CSF). To reach a larger population of people at-risk for early detection of these neurodegenerative diseases, Amprion is adapting its proprietary Prion Early Detection Science ℠ to detect the bad actors that drive these diseases in blood and saliva.
Parkinson’s & Alzheimer’s Blood Test
We are very optimistic that the misfolded soluble aggregates that we detect uniquely with Amprion’s technology will turn out to be the actual cause of these diseases and therefore the presence of these soluble misfolded aggregates in large amounts would be equivalent to either having the disease or having disease imminently. We are doing more and more research studies to validate these hypotheses.
Right now, we find that we have a very good correlation that our results are extraordinarily consistent using cerebrospinal fluid but if we want to do early detection for individuals who don’t have symptoms but may have a genetic predisposition or may have had head injuries and they’re concerned, we will need to adapt our technologies from cerebrospinal fluid to less invasive testings such as using saliva or blood samples and we are working on those with a very high priority and I can say that we’re making great progress but we are not ready for testing at the same accuracy in blood and CSF today, in blood and saliva today as we do in CSF. We anticipate that our efforts in analyzing blood will come to fruition in the next 12 to 18 months.
Spread the Word. Join The Fight. #JTFBrainHealth